Biohaven Ltd.
BHVN- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001935979
No open-market purchases or sales by Biohaven Ltd. insiders were filed in the last 90 days; 297 institutions reported holding it in 13F filings for Q2 2026, worth $2.13B in total; no superinvestor holds it.
Superinvestors holding BHVN, Q2 2026
No superinvestor reported holding BHVN in Q2 2026.
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of BHVN each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q1 2023
0 superinvestors holding at quarter end
- Sold out
- Soros Fund Management
Q4 2022
1 superinvestor holding at quarter end
- Reduced
- Soros Fund Management (−91.1%)
Q3 2022
1 superinvestor holding at quarter end
- Added
- Soros Fund Management (+81.1%)
Q2 2022
1 superinvestor holding at quarter end
- New
- Soros Fund Management
- Sold out
- Viking Global Investors
Q1 2022
1 superinvestor holding at quarter end
- Added
- Viking Global Investors (+177.0%)
Q4 2021
1 superinvestor holding at quarter end
- New
- Viking Global Investors
- Sold out
- Maverick Capital
Q3 2021
1 superinvestor holding at quarter end
- Reduced
- Maverick Capital (−65.8%)
Q2 2021
1 superinvestor holding at quarter end